Preclinical trials in autosomal dominant AD: Implementation of the DIAN-TU trial

Revue Neurologique

Volumn 169, Issue 10, 2013, Pages 737-743

  Mills, S M ^a   Mallmann, J ^a   Santacruz, A M ^a   Fuqua, A ^a   Carril, M ^a   Aisen, P S ^a   Althage, M C ^a   Belyew, S ^a   Benzinger, T L ^a   Brooks, W S ^a   Buckles, V D ^a   Cairns, N J ^a   Clifford, D ^a   Danek, A ^a   Fagan, A M ^a   Farlow, M ^a   Fox, N ^a   Ghetti, B ^a   Goate, A M ^a   Heinrichs, D ^a   Hornbeck, R ^a   Jack, C ^a   Jucker, M ^a   Klunk, W E ^a   Marcus, D S ^a   Martins, R N ^a   Masters, C M ^a   Mayeux, R ^a   McDade, E ^a   Morris, J C ^a   Oliver, A ^a   Ringman, J M ^a   Rossor, M N ^a   Salloway, S ^a   Schofield, P R ^a   Snider, J ^a   Snyder, P ^a   Sperling, R A ^a   Stewart, C ^a   Thomas, R G ^a   Xiong, C ^a   Bateman, R J ^a   more..

^a WASHINGTON UNIVERSITY   (United States)

Author keywords

Alzheimer's disease; Amyloid deposition; Amyloid beta (A ); Autosomal dominant; Clinical trial

Indexed keywords

BIOLOGICAL MARKER; PLACEBO;

ALZHEIMER DISEASE; AUTOSOMAL DOMINANT INHERITANCE; COMPARATIVE STUDY; CONFERENCE PAPER; DRUG DELIVERY SYSTEM; DRUG PACKAGING; GEOGRAPHIC DISTRIBUTION; HOME HEALTH RESEARCH; HUMAN; MEDICAL RESEARCH; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSERVATIONAL STUDY; PATIENT SAFETY; POPULATION; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); STUDY DESIGN;

ALZHEIMER'S DISEASE; AMYLOID DEPOSITION; AMYLOID-BETA (AΒ); AUTOSOMAL DOMINANT; AUTOSOMIQUE DOMINANTE; BÊTA-AMYLOÏDE; CLINICAL TRIAL; DÉPÔT DE SUBSTANCE AMYLOÏDE; ESSAI CLINIQUE; MALADIE D'ALZHEIMER;

ALZHEIMER DISEASE; BIOMEDICAL RESEARCH; CLINICAL TRIALS AS TOPIC; GENES, DOMINANT; HOME CARE SERVICES; HUMANS; MAGNETIC RESONANCE IMAGING; MEDICATION SYSTEMS, HOSPITAL; MONITORING, PHYSIOLOGIC; PATIENT SELECTION; RESEARCH DESIGN;

EID: 84884979769     PISSN: 00353787     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurol.2013.07.017     Document Type: Conference Paper

References (14)

1. R.J. Bateman, and W.E. Klunk Measuring target effect of proposed disease-modifying therapies in Alzheimer's disease Neurotherapeutics 5 3 2008 381 390 (Pubitemid 351952493)
2. R.J. Bateman, P.S. Aisen, B. De Strooper, N.C. Fox, C.A. Lemere, and J.M. Ringman Autosomal dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease Alzheimers Res Ther 3 1 2011 1
3. R.J. Bateman, C. Xiong, T.L. Benzinger, A.M. Fagan, A. Goate, and N.C. Fox Clinical and biomarker changes in dominantly inherited Alzheimer's disease N Engl J Med 367 9 2012 795 804
4. K. Blennow, J.O. Rinne, S. Salloway, J. Wei, R. Black, and M. Grundman Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate alzheimer disease Arch Neurol 69 8 2012 1002 1010
5. R.E. Gregg, L.A. Zech, E.J. Schaefer, D. Stark, D. Wilson, and H.B. Brewer Jr. Abnormal in vivo metabolism of apolipoprotein E4 in humans J Clin Invest 78 3 1986 815 821 (Pubitemid 16024820)
6. Z.H. Huang, C.Y. Lin, J.F. Oram, and T. Mazzone Sterol efflux mediated by endogenous macrophage ApoE expression is independent of ABCA1 Arterioscler Thromb Vasc Biol 21 12 2001 2019 2025 (Pubitemid 34219756)
7. J. Karlawish, M.S. Cary, J. Rubright, and T. Tenhave How redesigning AD clinical trials might increase study partners' willingness to participate Neurology 71 23 2008 1883 1888
8. P.C. May, R.A. Dean, S.L. Lowe, F. Martenyi, S.M. Sheehan, and L.N. Boggs Robust central reduction of amyloid-β in humans with an orally available non-peptidic β-secretase inhibitor J Neurosci 31 46 2011 16507 16516
9. J.C. Morris, P.S. Aisen, R.J. Bateman, T.L. Benzinger, N.J. Cairns, and A.M. Fagan Developing an international network for Alzheimer research: the dominantly inherited alzheimer network J Clin Invest 2 10 2012 975 984
10. S. Ostrowitzki, D. Deptula, L. Thurfjell, F. Barkhof, B. Bohrmann, and D.J. Brooks Mechanism of amyloid removal in patients with alzheimer disease treated with gantenerumab Arch Neurol 69 2 2012 198 207
11. J.M. Ringman, J. Grill, Y. Rodriguez-Agudelo, M. Chavez, and C. Xiong Commentary on "a roadmap for the prevention of dementia II: Leon Thal Symposium 2008." Prevention trials in persons at risk for dominantly inherited Alzheimer's disease: opportunities and challenges Alzheimers Dement 5 2 2009 166 171
12. S. Salloway, R. Sperling, S. Gilman, N.C. Fox, K. Blennow, and M. Raskind A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease Neurology 73 24 2009 2061 2070
13. T. Sato, Y. Ishihama, and Y. Oda Quantitative proteomics of mouse brain and specific protein-interaction studies using stable isotope labeling Methods Mol Biol 359 2007 53 70 (Pubitemid 350183221)
14. R.A. Sperling, C.R. Jack Jr., S.E. Black, M.P. Frosch, S.M. Greenberg, and B.T. Hyman Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup Alzheimers Dement 7 4 2011 367 385